Schering Corporation

Merck Sharp + Dohme Corp.

Other

Merck Sharp + Dohme B.v.

Winifred W Prosise

Shahriar Shane Taremi

Paul Reichert

Vincent Stewart Madison

Wenyan Wang

Li Xiao

Charles A Lesburg

Hung V Le

Ramesh Kashi

Jun Zou

Kuo-Chi Cheng

Jian-Jun Liu

Corey Strickland

Peter Orth

Thierry Olivier Fischmann

Andrea Van Elsas

Patricia C Weber

Hans Van Eenennaam

Laurence Fayadat-Dilman

Veronica Juan

Nanhua Hugh Yao

Lars Guelen

Svetlana Sadekova

Amy M Beebe

Chakravarthy Nachu Narasimhan

Giovanna Scapin

Chakravarthy Narasimhan

Jason Ka Jen Cheung

Xiaoyu Yang

Jerelyn Wong

Ramesh S Kashi

Crystals of pembrolizumab and structurally similar anti-PD-1 monoclonal antibodies are provided, as well as methods of producing such crystals, and uses of compositions comprising such antibody crystals, e.g. in treatment of cancers. The present invention satisfies these needs and more by providing pembrolizumab crystals and a method producing pembrolizumab crystals. One embodiment of the method of the invention produces crystals suitable for X-ray diffraction, and the inventors herein used such crystals to solve the three-dimensional structure of pembrolizumab to 2.3 A resolution.

Crystals of anti-human PD-1 monoclonal antibodies

The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.

Anti-CD27 antibodies

Crystalline forms of antibodies to human IL-23, such as antibodies to human IL-23p19 , are provided, as well as methods of producing such crystalline forms, and uses of such crystalline forms, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. In various embodiments, the anti-hulL-23 antibody crystals, such as anti-hulL-23p19 antibody crystals of the present invention are obtainable by batch crystallization methods, vapor diffusion methods, liquid-liquid diffusion methods, and dialysis. In other aspects, the invention relates to suspensions of the crystalline anti-hulL-23 antibodies of the present invention, including those at higher concentrations and lower viscosities than would be possible with a corresponding non-crystalline solution at the same concentration of antibody. In other embodiments, the anti-huiL-23 antibody crystals of the present invention have increased stability, i.e. they maintain biological activity of the anti-huiL-23 antibody, such as anti-huiL-23p 19 antibody, longer than corresponding solution formulations.

Crystalline anti-human IL-23p19 antibodies

The present invention relates to Pregnane X receptor (PXR) polypeptides and crystals that are useful, for example, for crystallization and in assays for identification of modulators of PXR.

Crystal of pregnane X receptor fused to steroid receptor coactivator-1

The present invention relates, inter alia, to PXR polypeptides and crystals that are useful, for example, for crystallization and in assays for identification of modulators of PXR.

Pregnane X receptor compositions, crystals and uses thereof

The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure-based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.

Catalytic domain of ADAM33 and methods of use thereof

The invention relates to the purification and crystallization of hepatitis C virus (HCV) NS3/NS4A polypeptide complex. Also, crystallization conditions for NS3/NS4A are provided. Further, the atomic coordinates for the NS3/NS4A protein are disclosed. Examples of its use for the determination of the three-dimensional atomic structures of HCV NS3/NS4A with substrate(s) or substrate analog(s) or inhibitor complexes are also provided.

Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same

A method for determining if an enzyme can cleave a substrate or if a substance is an inhibitor of the enzyme using surface plamon resonance.

Surface plasmon resonance based enzymatic assay

Growing community of inventors

Ramsey, NJ, United States of America

Winifred W Prosise